key: cord-0978609-ieqpee9z
authors: Gothong, Chikara; Singh, Lakshmi G.; Satyarengga, Medha; Spanakis, Elias K.
title: Continuous glucose monitoring in the hospital: an update in the era of COVID-19
date: 2021-11-29
journal: Curr Opin Endocrinol Diabetes Obes
DOI: 10.1097/med.0000000000000693
sha: b4b72f2993cde5faba59d733d67eb623a15fa6b3
doc_id: 978609
cord_uid: ieqpee9z

Continuous glucose monitoring (CGM) systems are Food and Drug Administration approved devices for the ambulatory setting; however, they remain investigational systems for inpatient use. This review summarizes the most recent and relevant literature on the use of continuous glucose monitoring in the hospital setting. RECENT FINDINGS: CGM provides real-time glucose data that enable healthcare professionals to make proactive and timelier clinical decisions with regards to diabetes management. CGM devices appear to be safe and accurate systems for glucose monitoring in the hospital setting. Real-time CGM systems and glucose telemetry can decrease hypoglycemia and reduce hyperglycemia in hospitalized patients with diabetes. Remote glucose monitoring decreases the need of frequent Point-of-care checks and personal protective equipment use while also mitigating staff exposure risk which is timely in the advent of the COVID-19 pandemic. Although most nursing staff have limited exposure and training on CGM technology, early studies show that CGM use in the hospital is well received by nurses. SUMMARY: Given the evidence in the current literature regarding CGM use in the hospital, CGM devices may be incorporated in the inpatient setting.

More than 10.5% of the US population have either diagnosed or undiagnosed diabetes [1] . Uncontrolled diabetes leads to microvascular and macrovascular complications resulting in the development of multiple comorbidities and eventual hospitalizations [2, 3] . The high prevalence of diabetes in the inpatient setting, which accounts for over 25% of hospitalized patients, leads to increased hospital-related costs [4, 5] .

Among hospitalized patients, the presence of dysglycemia -defined as hyperglycemia, hypoglycemia, or significant glycemic variability-has been associated with adverse clinical outcomes [6] . Currently, bedside point-of-care glucose (POC) is the recommended method of glucose testing for hospitalized patients with diabetes [7] . Continuous glucose monitoring (CGM) systems offer a different modality of glucose monitoring compared to traditional POC, measuring glucose concentration in the interstitial fluid every few minutes. CGM systems have revolutionized outpatient glucose monitoring since its US Food and Drug Administration (FDA) approval in 1999 [8] . In the hospital, multiple studies have examined the use of CGM devices in the noncritical and critical care settings, some showing promising results [9, 10] . Most of the inpatient studies performed assessed accuracy of CGM compared to POC, which is not considered standard of reference. To date, there are no studies comparing CGM glucose with those from a laboratory glucose analyzer as the reference. In addition, only a few studies examined whether CGM devices can have additional benefits compared to POC in hospitalized patients with diabetes or hyperglycemia. Thus, CGM has not yet been approved by the FDA to be utilized in the inpatient setting.

On March 11, 2020 , the World Health Organization (WHO) declared Coronavirus-19 (COVID- 19) a global pandemic. Patients with diabetes were found to have an increased risk for developing severe COVID-19 [11] and have a higher risk of mortality [12, 13] compared to the general population [14] . To help conserve personal protective equipment (PPE) use and mitigate staff exposure in the inpatient hospital setting, the FDA issued guidance which did not object to the use of CGM devices in the inpatient setting during the pandemic [15] [16] [17] . Previous articles have reviewed the use of CGM devices in the hospital in both the noncritical care and critical care setting [9, [18] [19] [20] [21] . In this article, we present a comprehensive review focusing on studies published after the COVID-19 pandemic declaration that utilized CGM technology in the hospital. We included studies that used CGM in adult, nonpregnant patients who were either observed or admitted to the hospital for medical or surgical conditions and excluded studies that were done for purely research purposes. We excluded publications that solely included the pediatric and pregnant population. Publications which used CGM combined with continuous subcutaneous infusion ('insulin pumps') or automated insulin delivery systems ('closed loop systems') were also excluded from this review.

The majority of the studies conducted in non-COVID-19 patients evaluated the accuracy of CGM devices and were performed in the noncritical care setting, including a large group of medical and surgical patients (Table 1 ). There were only two single-center RCTs in the noncritical care setting that enrolled patients with type 2 diabetes mellitus (T2DM) evaluating glycemic outcomes with use of real-time-CGM [22 && ,23] . For the accuracy studies that utilized the Dexcom G6 system (Dexcom, Inc., San Diego, CA, USA), the overall mean absolute relative difference (MARD) ranged between 9.4-12.9% and the median absolute relative difference (ARD) ranged between 9.9 and 10.5% [24 && ,25-27] . A large multicenter pooled accuracy analysis of CGM data from 218 medicine and surgery patients (n ¼ 4067 matched glucose pairs) with diabetes revealed a MARD of 12.8% and median ARD of 10.1% [24 && ]. Dexcom G6 system was evaluated in the perioperative setting in 10 patients with diabetes scheduled to undergo elective surgery and reported an overall MARD of 9.4% [25] . Another perioperative accuracy study which involved patients without a history of diabetes who underwent coronary artery bypass surgery showed an overall MARD of 12.9% and a median ARD of 10.5% and noted intermittent signal loss during surgery likely secondary to electrocautery interference [27] . Given the concern for possible inaccuracy during certain imaging procedures, another study assessed CGM accuracy during certain radiologic procedures (X-rays, computed tomography scan, and angiography), reporting an overall MARD of 13.3% preimaging and 12.7% postimaging [28] .

In addition to evaluating accuracy, studies have been conducted examining the utility of CGM devices in the prevention of hypoglycemia and management of hyperglycemia [22 && ,23] . Utilizing the glucose telemetry system (GTS), a randomized controlled trial (RCT) by Singh et al. enrolled 72 patients with T2DM at higher risk of inpatient hypoglycemia randomized to either real time-CGM/GTS or POC [22 && ]. GTS utilizes Bluetooth technology and

Real time-CGM and glucose telemetry has been shown to be beneficial in the early detection and prevention of hypoglycemia as well as a tool to decrease hyperglycemia.

Real time-CGM allows healthcare providers to observe and anticipate glycemic trends resulting in more proactive and timelier clinical decisions.

Remote glucose monitoring/glucose telemetry results in decreased POC checks, decreased use of personal protective equipment (PPE) and mitigation of staff exposure risk.

Diabetes and the endocrine pancreas I [32] . Another study assessed the association of mean amplitude of glycemic excursions (MAGEs) with clinical outcomes using CGM data in patients with 

Most of the published studies in COVID-19 patients focused on feasibility and accuracy of inpatient CGM in COVID-19 patients to improve glycemic outcomes and reduce burden for healthcare professionals (Table 2) . Notably, most studies were either observational studies or case reports with a small number of subjects. To date, there are no published RCTs examining CGM devices in COVID-19 patients. Studies reporting accuracy of CGM predominantly utilized Dexcom G6 CGM reporting overall MARD ranging between 9.77% and 14% [35] [36] [37] [38] [39] . There were only two studies [35, 40] that utilized the Guardian Connect (Enlite) CGM with only one study reporting the overall MARD of 13.1% [35] . An approach to overcome concerns about CGM accuracy was suggested by Faulds et al. where a hybrid CGM and POC glucose monitoring protocol to guide insulin adjustments was implemented. Nursing leadership inserted CGMs in patients requiring intravenous insulin in the critical care setting. POC glucose were used to adjust insulin rates as needed but also validate the CGM sensor. Once initial validation was achieved, CGM data alone was used for clinical decision making and insulin titration with continuation of POC to maintain validation. After ICU transfer, CGM was used alone without POC [41] . Authors enrolled a total of 19 medical ICU patients requiring intravenous insulin managed by this protocol showing feasibility of this hybrid approach. Overall MARD was 13.9% AE 7.8% on day 1 and 13.5% AE 8.1% on days 2 through 7 with a 71% reduction in POC use [38 && ]. Sensor insertion was done by a trained nurse, nurse practitioner or healthcare professional in most of the studies [35] [36] [37] 38 && , 39, 42, 43] . For the studies using Dexcom G6 system, glucose data was transmitted to Dexcom receivers [36, 42] , Android phones [38 && ] or both iPad and iPhones [35] and were placed close to the patient's room. These receiving devices were within 10-20 feet from the transmitter to ensure Bluetooth transmission. This direct view of glucose data from outside the patients' rooms allowed the healthcare team to monitor glucose data without entering the patients' rooms. Other studies used remote glucose monitoring with the GTS [37,39,44 & ] or Medtronic Guardian Connect System using the web-based CareLink software accessed through minimized browser windows [40] .

Another study described the use of a CGM/POC hybrid protocol that combined glucose telemetry with Glucommander, a computer-based algorithm that provides adjustments of intravenous insulin delivery. This proof-of-concept study reported a mean time below range (TBR) (<70 mg/dL) was 0.6 AE 0.9%, TIR (70-180 mg/dL) of 71.4 AE 13.9%, time between 180-250 mg/dL of 19.8 AE 97%, and time above range (TAR) (>250 mg/dL) of 7.5 AE 7.3%. During protocol use, 75.7% of sensor glucose values >100 mg/dL were within 20% of the reference POC, with a mean number of 8.24 AE 3.06 POC per day (63% reduction). Sensor readings were lower in states of hypoperfusion (i.e., pulseless electrical activity, shock, and therapeutic hypothermia) with signal loss occurring during cardiac arrest and defibrillator use. Sensor accuracy was also impacted by position changes including pronation or inadvertent sensor compression [44 & ].

As CGM is FDA approved and used predominantly in the outpatient setting, most nursing staff had limited exposure and training on CGM technology. Chow et al. assessed nursing staff perception and acceptance of real time-CGM revealing 63% of participating nurses viewed real time-CGM as a helpful tool improving clinical care for patients with diabetes and COVID-19. Additionally, 49% of nursing staff reported real time-CGM reduced PPE use [42] . Other studies noted reduction in POC ranging between 50 and 63% [36,42,44 & ]. While implementation of a hybrid CGM and POC protocol by Faulds et al. was well received by nursing staff, there was unanimous consensus amongst them that the protocol was excessively lengthy [38 && ]. Nursing staff also commented components for CGM use (i.e., receiver, phone, cords) and training materials were crowding their workstations.

Gomez et al. used Freestyle Libre CGM to examine the association of glycemic control metrics with clinical outcomes in the ICU and non-ICU setting [43] . No differences were seen in TIR, TAR, TBR, coefficient of variation or glucose management indicator in patients with or without admission to ICU, ARDS or AKI, or with the composite metric of these complications. In a subgroup analysis for patients with hyperglycemia without known history of diabetes, higher TAR>180 mg/dL was seen in patients with AKI (18 vs. 1%, P ¼ 0.01), and in those -Use of CGM resulted in 71% reduction in POC use -Negative association found between BMI and MARD (coefficient -Sensor readings were lower during hypoperfusion states (PEA, shock) and with signal loss during cardiac arrest and defibrillator use.

-Sensor accuracy was also impacted during therapeutic hypothermia and position changes including pronation or inadvertent sensor compression. with the composite outcome (22.5% vs. 16%, P ¼ 0.04). Freestyle Libre CGM was also used to evaluate the association of glycemia with outcomes related to COVID-19 infection. Patients with the composite adverse outcomes (ICU admission, need for mechanical ventilation, or morbidity with critical illness) had significantly higher TBR (4.43 AE 11.4% vs. 0.54 AE 0.65%) [P < 0.01] and higher mean glucose values (174 AE 49.0 vs.144 AE 21.2 mg/dL, P < 0.01) than those without composite adverse outcomes [45] .

The use of inpatient CGM confers numerous benefits with minimal risks. With the COVID-19 pandemic, the importance of remote glucose monitoring is highlighted now more than ever. Real time-CGM has been shown to be useful in the early detection and prevention of hypoglycemia as well as a tool to decrease hyperglycemia. Real time-CGM provides glycemic trends that may be used to enable more proactive and timelier decisions for diabetes management to reduce clinically significant events such as hypoglycemia or hyperglycemia. CGM devices also decreases the need for healthcare workers to enter the patients' rooms and reduces frequent POC checks which can be uncomfortable and painful for patients and increases nursing workload. Furthermore, CGM use has led to a reduction in PPE use and significantly mitigates the risk of exposure for healthcare staff.

Prior to the advent of POC testing, serum blood glucose (SBG) samples were drawn and brought to the central lab for analysis. Although SBG is more accurate, this was a cumbersome and time-consuming process that at times, can result in delays in patient care. In the last few decades, glucometers became the standard of care in the inpatient setting mainly due to their convenience. Similarly, we believe that CGM devices will eventually be utilized in the hospital as standard of care as they provide a more robust and enriched data set of glycemic values than glucometers, helping clinicians and nurses to safely manage patients with diabetes without increasing workload. In conclusion, although CGM devices are currently seen as novel systems, it is only a matter of time when CGM systems will be approved for use in the inpatient setting.

National Diabetes Statistics Report. U.S. Dept of Health and Human Services, Prevention CfDCa

American Diabetes A. 10. Cardiovascular disease and risk management: standards of medical care in diabetes

American Diabetes A. 11. Microvascular complications and foot care: standards of medical care in diabetes

Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes

American Diabetes A. Economic costs of diabetes in the U.S in 2017

Management of diabetes and hyperglycemia in hospitals

American Diabetes A. 15. Diabetes care in the hospital: standards of medical care in diabetes

Introduction: History of Glucose Monitoring

Advancing the use of CGM devices in a non-ICU setting

Designing the glucose telemetry for hospital management: from bedside to the nursing station

Impact of diabetes mellitus on clinical outcomes in patients affected by Covid-19

Excess mortality in COVID-19-positive versus COVID-19-negative inpatients with diabetes: a nationwide study

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Epidemiology Working Group for Ncip Epidemic Response CCfDC, Prevention

Coronavirus (COVID-19) Update: FDA allows expanded use of devices to monitor patients' vital signs remotely 2020

Fact Sheet for Healthcare Providers: Use of Dexcom Continuous Glucose Monitoring Systems During the COVID-19 Pandemic

Freestyle Libre 14 Day System Now Available in U.S. For Hospitalized Patients With Diabetes During COVID-19 Pandemic

Inpatient continuous glucose monitoring and glycemic outcomes

Continuous glucose monitoring: a review of the technology and clinical use

Continuous glucose monitoring in the hospital

Continuous glucose monitors and automated insulin dosing systems in the hospital consensus guideline

Reducing inpatient hypoglycemia in the general wards using real-time continuous glucose monitoring: the glucose telemetry system, a randomized clinical trial

Glucose as the fifth vital sign: a randomized controlled trial of continuous glucose monitoring in a nonicu hospital setting

Accuracy of dexcom G6 continuous glucose monitoring in non-critically Ill hospitalized patients with diabetes

This is the largest multicenter study that assessed the accuracy of CGM in the inpatient noncritical care setting

A pilot study of the feasibility and accuracy of inpatient continuous glucose monitoring

Performance of a factory-calibrated, realtime continuous glucose monitoring system during elective abdominal surgery

Continuous glucose monitoring in the operating room and cardiac intensive care unit

Accuracy and precision of continuous glucose monitoring in hospitalized patients undergoing radiology procedures

The effect of continuous glucose monitoring in preventing inpatient hypoglycemia in general wards: the glucose telemetry system

This is a pilot study that wirelessly transmitted glucose data to the nursing station, creating a remote contiuous glucose monitoring system otherwise known as the 'glucose telemetry system

Comparison of the freestyle libre pro flash continuous glucose monitoring (cgm) system and point-of-care capillary glucose testing in hospitalized patients with type 2 diabetes treated with basal-bolus insulin regimen

Flash glucose monitoring compared to capillary glucose levels in patients with diabetic ketoacidosis: potential clinical applications

Feasibility of real-time continuous glucose monitoring telemetry system in an inpatient diabetes unit: a pilot study

Mean amplitude of glycemic excursions in septic patients and its association with outcomes: A prospective observational study using continuous glucose monitoring

Nocturnal hypoglycemia in patients with diabetes discharged from ICUs: a prospective two-center cohort study

Continuous glucose monitoring in critically ill patients with covid-19: results of an emergent pilot study

Continuous glucose monitoring in the intensive care unit during the COVID-19 pandemic

Feasibility of inpatient continuous glucose monitoring during the COVID-19 pandemic: early experience

Use of continuous glucose monitor in critically ill COVID-19 patients requiring insulin infusion: an observational study

Use and accuracy of inpatient CGM during the COVID-19 pandemic: an observational study of general medicine and ICU patients

Remote glucose monitoring of hospitalized, quarantined patients with diabetes and COVID-19

Facilitators and barriers to nursing implementation of continuous glucose monitoring (CGM) in critically ill patients with COVID-19

Outcomes and healthcare provider perceptions of real-time continuous glucose monitoring (rtCGM) in patients with diabetes and COVID-19 admitted to the ICU

Glycemic control metrics using flash glucose monitoring and hospital complications in patients with COVID-19

Remote continuous glucose monitoring with a computerized insulin infusion protocol for critically ill patients in a COVID-19 medical ICU: proof of concept

Thresholds of glycemia and the outcomes of COVID-19 complicated with diabetes: a retrospective exploratory study using continuous glucose monitoring

Financial support and sponsorship This work was supported in part by the VA MERIT award (#1I01CX001825) from the United States (U.S.)

Research and Development Service.

Papers of particular interest, published within the annual period of review, have been highlighted as: & of special interest && of outstanding interest